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Clinical Microbiology and Infection Control Department  
Basurto Hospital, Avenida Montevideo – Bilbao 
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1. Introduction 
Candida bloodstream infections (BSI) have become a major healthcare problem, specially in 
tertiary- care hospitals worldwide (Al-Jasser & Elkhizzi, 2004, Almirante et al., 2005, Alonso-
Valle et al., 2003, Atunes et al., 2004 Asmundsdottir et al., 2002, Costa et al., 2000, Fraser et 
al., 1992, Garbino et al., 2002, Luzzati et al. 2000, Marchetti et al., 2004, Pappas et al., 2003, 
Viudes et al., 2002). Several risk factor identified among patients hospitalized for long 
periods such as the exposition to broad spectrum antimicrobial and/or immunosuppressive 
chemotherapy, parenteral nutrition, and invasive medical procedures have contributed to 
this fact (Blumberg et al., 2001, Fraser et al., 1992). Despite some improvements in fungal BSI 
diagnosis during last years, candidemia diagnosis remains difficult. Besides, following the 
data appeared in the classical study from Berenguer and colleagues, only 50% of patients 
with disseminated candidiasis will have positive blood cultures and even fewer will have an 
antemortem diagnosis (15% to 40%) (Berenguer et al., 1993). Therefore, invasive candidemia 
is not easy to diagnose, has an expensive treatment and finally is a serious, often life- 
threatening infection (Girmenia et al., 1996, Messer et al., 2009). 
Although the incidence of candidemia has increased steadily among hospitalized patients 
during the eighties and nineties, recent series suggest that This increase has stabilized, but 
with great variations between different geographical locations with similar socio-economical 
development even in the same continent. For instance, in The Netherlands an increasing 
incidence of candidemia has been reported during the period between eighties and nineties 
(Voss et al., 1996) but on the other hand, in a neighbouring country such as Switzerland the 
incidence of Candida BSI infections remained unchanged during the same period (Marchetti 
et al., 2004). Therefore, it seems that there are some differences in the epidemiology of 
candidemia between different countries. 
Besides, in recent years, a trend towards increasing resistance to both traditional and more 
recently introduced antifungal agents has been observed amongst invasive Candida 
infections, underscoring the need for continuous surveillance to monitor trends in incidence, 
species distribution, and antifungal drug susceptibility profiles. 
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The epidemiology of candidemia has been extensively studied in many countries and there 
are some large series published in this field (Alonso-Valle et al., 2003, Atunes et al., 2004, 
Banerjee et al., 1991, Colombo et al., 2006, Diekema et al., 2002, Kao et al., 1999, Messer et al., 
2009, San Miguel et al., 2005, Silva et al., 2004, Tortorano et al., 2004, Trick et al., 2002). But, 
most of the data on candidemia in Spain until recent days are limited to retrospective 
reviews of medical records or observational studies conducted in a limited geographical 
area (Almirante et al., 2005, Alonso-Valle et al., 2003, Pemán et al., 2002, Pemán et al., 2011). 
Regarding the Spanish data available on antifungal resistance is often assessed by occasional 
surveys or reported in summaries of sporadically occurring cases of treatment failures. The 
purpose of such investigations is to monitor levels of susceptibility to different agents. 
However, long-term prospective studies of antifungal susceptibility have the advantage of 
eliminating a number of variable factors which may affect these assessments. Some of these 
factors include temporary changes in patterns of Invasive Candida infections (as stated 
before) and transient alterations in antifungal resistance due to special conditions (e.g. 
candidemia outbreaks in ICUs). Consequently, the epidemiological data about candidemia 
and its impact in the healthcare system is unknown, and no reliable nationwide data are 
available. In order to make a realistic global perspective of invasive Candida BSI, we 
designed a prospective laboratory-based surveillance study comprising 40 tertiary care 
hospitals across the country, to assess the incidence, species distribution, frequency of 
antifungal resistance, and risk factors for candidemia. 
2. Materials and methods 
Study design 
A prospective laboratory-based surveillance was established to monitor the predominant 
Candida species and antifungal resistance patterns of nosocomial and community-acquired 
invasive Candida infections via a network of sentinel hospitals distributed by geographic 
location across the country.  
The participating institutions include 40 medical centers which provide medical care either 
to adults and children in several medical specialties. Each participant hospital contributed 
prospectively clinical and epidemiological results (organism identification, date of isolation, 
hospital location, intrinsic and extrinsic risk factors for candidemia) on clinically significant 
consecutive blood culture isolates of Candida spp. (one isolate per patient) detected during 
the 12-month period from June, 2008 through June, 2009. All isolates were saved on agar 
slants and were sent on a trimestral basis to the Mycology Laboratory at Basurto Hospital 
for storage, further characterization and reference susceptibility testing. 
Clinical definitions 
Clinical and case definitions were according the NHSN (formerly NNISS) methodology. 
Statements defining a case and other clinical conditions are summarized in Table 1.  
Quality control measures of clinical data 
The clinical case report list of each hospital was compared with the isolates received at 
Basurto Hospital to perform the antifungal susceptibility in order to verify that neither cases 
nor isolates were missed. Audits of medical records to verify accuracy of data and 
completeness were performed on 25% of cases. 
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Incident  case of candidemia: The incident isolation of Candida spp. from a blood culture. 
New incident case of candidemia: An episode of candidemia occurring more than 30 days 
 after the initial incident isolation. 
Breakthrough candidemia: The incident isolation of Candida spp. from a blood culture 
 from a patient receiving systemic antifungal therapy for 
 any reason. 
Fever:  Peripheral body temperature equal or higher than 37.8°C 
Neutropenia: An absolute neutrophil count of less than 500 cells / mm3.  
Adult patients: All patients whose  age was over 14 years old. 
Table 1. Definitions according to NHSN (formerly NISS) used in this study 
In vitro susceptibility testing 
Antifungal susceptibility tests were performed by using the broth microdilution assay 
according to the methodology recommended by the CLSI (formerly known as NCCLS), 
document M27-A2 (NCCLS, 2002) using a microtiter plate. Each isolate was tested against 
different antifungal drugs at the indicated concentration range suggested in the CLSI 
document. Quality control (QC) was ensured by testing the CLSI recommended QC strains, 
C. krusei ATCC 6258, and C. parapsilosis ATCC 22019.The MIC endpoint for amphotericin B, 
azoles and echinocandins and interpretative MIC breakpoints for azoles and echinocandins 
were those suggested by the CLSI document M27-A2, but for the definition of the 
amphotericin B MIC breakpoints we used the values suggested from a previous study 
published by Nguyen et al. (Nguyen et al., 1998). 
Statistical analysis 
The numbers of admissions and patient-days were collected to calculate incidence rates. The 
incidence rate for each hospital was calculated as the number of candidemias per 1,000 
admissions, whereas the overall incidence was determined using summed denominators of 
patient-days and admissions to calculate pooled mean rates. The data generated during the 
year of the surveillance on the different risk factors, underlying diseases, morbidity and 
mortality were recorded in a Microsoft Access 2003 (Microsoft Corporation, Redmond, WA) 
based case report database. Categorical data were analyzed using Chi-square or Fisher’s 
exact tests as appropriate, and continuous variables were compared using the t-test or 
Wilcoxon test according to the significance of the normality test. Spearman rank-order 
correlation was used to measure the relationship between the MICs of fluconazole and 
voriconazole. We performed univariate and multivariate analysis of factors associated with 
candidemia caused by isolates with decreased susceptibility to fluconazole. Variables 
significant at p-values of less than 0.05 by univariate analysis were included in a 
multivariate model using a repeated measures logistic regression model (backward and 
forward). Data were analyzed using the SPSS 11.0.1 software (SPSS, Inc. Chicago, IL) and 
Stata 8.0 (Stata Corporation, Lenexa, TX). 
3. Distribution of Candida blodostream infections  
During the 12-month study period a total of 984 Candida BSIs were reported. The calculated 
overall incidence was 1.09 cases per 1,000 admissions, however the incidence rate changed a 
lot between the 40 centers enrolled in this study and ranged from 0.76 to 1.49 cases per 1,000 
admissions. 
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Among the invasive Candida BSIs, 45.3 % occurred in patients in an medical service, 23.5% 
in patients hospitalized in an intensive care unit, 17.6% in patients in a surgical ward, 7.41% 
in a pediatric ward and finally 4.06% in other services. Most of the patients (98.7%) were 
hospitalized and only nine of them were outpatients at the time of diagnosis. 
Candidemia incidence was slightly higher in males (64.02% of the case patients) and the 
global average age at the onset of the episode was 41 years with a median age was 53 years 
among adult patients and 7 months among children. 
The frequency of BSIs due to the most frequently isolated species of Candida in the study 
sites are presented in Table 2.  
 
Species No. (%) of cases Range (in %) between clinical settings 
C. albicans 483 (49.08%) 27 – 54 
C. parapsilosis 204 (20.73%) 7 – 40 
C. glabrata 134 (13.61%) 2 – 14 
C. tropicalis 106 (10.77%) 16 – 29 
C. krusei 21 (2.13%) 0 – 9 
Other species a 36 (3.65 %) 0 – 4 
a Species with less than 10 isolates are included in this category. This category includes C. famata, C. 
lusitaniae, C. pelliculosa and Candida spp. 
Table 2. Species distribution and incidence among 984 cases of candidemia detected during 
prospective sentinel surveillance in Spain from June 2008 to June 2009 
Overall, the 49.08% of the cases were attributable to C. albicans, 20.73% were attributable to 
C. parapsilosis, 13.61% were attributable to C. glabrata, 10.77% were attributable to  
C. tropicalis, 2,13% to C. krusei and  the rest of the cases (3.65%) were attributable to other 
species. The distribution of Candida species among adult population was similar to the one 
found in pediatric cases, however, the distribution of species varied considerably when 
analyzed between centers as it has been reflected in the ranges specified in Table 2. The 
species distribution among our study isolates is similar to that described by Pfaller et al. 
(Pfaller et al., 1998) in Latin America with data collected by the Sentry Antimicrobial 
Surveillance Program. As Pfaller and colleagues described previously, the proportion of 
species isolated varies considerably among medical centers beign unclear the reasons for 
such differences and they could be attributed to many different influences. 
Table 3 summarizes the overall clinical characteristics and outcome of the 984 candidemia 
cases identified.  
At the time of candidemia diagnosis, neoplasia was documented for 195 (19.84%) patients, 
35 of which (17.94%) were affected with hematologic malignancies Prior surgery was 
recorded from 311 (31.6%) patients (311 of a total of 984), being most of them abdominal 
surgeries (64% of total surgical patients). Two third of the patients (66.97%) had a central 
venous catheter and one quarter (26.93%) of them were under mechanical ventilation. 
Neutropenia and dialysis were rare conditions which was only documented in only 35 case 
patients (3.55%) and 12 patients (1.21%) respectively. Invasive Candida spp. infection 
complications such as endocarditis or endophalmitis were infrequent and with 17 cases 
documented for the former complication (2%) and 3 patients for the later.  
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Variable 
Value for all total 
cases 
 Value for species  
C. 
albicans 
C. 
parapsilosis 
C. 
tropicalis 
C. 
glabrata 
Average age (range) 41 (0–96) 46 (0–92) 48 (0–96) 33 (0–89) 52 (0–88) 
No. of males 577 (58.64) 
273 
(56.52) 
182 (89.21) 51 (48.11) 
62 
(46.27) 
No. of outpatients 7 (0.71) 3 (0.62) 1 (0.49) 3 (2.83) 0 (0.00) 
Median no. of days (range)  until 
candidemia 
20 (0–385) 
20 (0–
114) 
19 (0–385) 19 (0–47) 
19 (0–
115) 
No. of cases of underlying diseases      
Cancer 311 (31.61) 
127 
(26.29) 
86 (42.16) 34 (32.07) 
26 
(19.40) 
Hematological malignancy 20 (2.03) 5 (1.04) 6 (2.94) 1 (0.94) 1 (0.75) 
Coronary artery disease 82 (8.33) 33 (6.83) 23 (11.27) 5 (4.72) 8 (5.97) 
Chronic Obstructive Pulmonary disease 
(COPD) 
71 (7.21) 40 (8.28) 11 (5.39) 5 (4.72) 9 (6.71) 
Neurological disease 35 (3.55) 14 (2.80) 12 (5.88) 2 (1.89) 2 (1.49) 
Diabetes 120 (12.20) 53 (10.97) 22 (10.78) 8 (7.55) 
20 
(14.93) 
Organ transplantation 45 (4.57) 14 (2.90) 21 (10.29) 2 (1.89) 3 (2.23) 
HIV infection 33 (3.35) 18 (3.73) 3 (1.47) 3 (2.83) 3 (2.24) 
Parenteral drug abusers 22 (2.23) 10 (2.07) 4 (1.96) 2 (1.89) 1 (0.75) 
No. of patients with characteristic      
Previous or actual corticosteroid 
therapy 
180 (18.29) 80 (16.56) 50 (24.50) 13 (12.26) 
21 
(15.67) 
Immunosuppressive therapy and/or 
neutropenia 
265 (26.93) 
102 
(21.12) 
75 (36.76) 28 (26.41) 
28 
(20.90) 
In the ICU at diagnosis 252 (25.61) 
120 
(24.84) 
68 (33.33) 21 (19.81) 
25 
(18.66) 
Mechanical ventilation 265 (26.93) 
133 
(27.54) 
71 (34.80) 15 (14.15) 
26 
(19.40) 
Hemodialysis at diagnosis 12 (1.22) 2 (0.41) 4 (1.96) 1 (0.94) 3 (2.24) 
Previous surgery 311 (31.61) 
148 
(30.64) 
82 (40.20) 19 (17.92) 
36 
(26.87) 
Central venous catheter 659 (66.79) 
295 
(61.07) 
187 (91.66) 52 (49.06) 
61 
(45.52) 
Urinary catheter 450 (45.73) 
207 
(42.86) 
112 (54.90) 31 (29.25) 
52 
(38.81) 
Prior antibiotic therapy 747 (75.91) 
337 
(69.77) 
106 (51.96) 60 (56.60) 
71 
(52.98) 
Prior fluconazole use 78 (7.93) 29 (6.00) 10 (4.90) 12 (11.32) 9 (6.71) 
Death attributed to candidemia 134 (13.62) 60 (12.42) 20 (9.80) 13 (12.26) 
15 
(11.19) 
Mortality due to other conditions 103 (10.47) 48 (9.94) 36 (17.65) 7 (6.60) 
14 
(10.45) 
Overall mortality 237 (24.10) 
108 
(22.36) 
56 (27.45) 20 (18.87) 
29 
(21.64) 
 
Table 3. Demographics, clinical characteristics, and mortality for Candida spp. BSI episodes 
identified during prospective sentinel surveillance conducted in Spain from June 2008 to 
June 2009. 
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There were no statistically significant differences when the risk mentioned above were 
analyzed for the pediatric population of patients. 
4. Antifungal susceptibility 
In vitro susceptibility testing of the 984 BSI isolates of Candida species against amphotericin 
B, fluconazole, voriconazole, caspofungin and anidulafungin revealed that when globally 
analyzed Candida strains causing BSI are rarely resistant to a wide number of antifungal 
agents. However, the resistance rates among the different species vary a lot as it can be 
shown on Table 4.  
 
Species 
Antifungal 
agent 
 MIC 
(ug/ml) 
 No. of  resistant or SDD 
isolates 
Range 50% 90% 
C. albicans (483) Amphotericin B 
0.125–
1.0 0.5 1.0 0 (0.00) 
 Fluconazole 0.125–64 0.5 2.0 10 (2.07) 
 Voriconazole < 0.03–4 0.03 0.03 5 (1.04) 
 Caspofungin <0.03–4 0.25 2.0 3 (0.62) 
 Anidulafungin <0.03–2 0.03 0.03 0 (0.00) 
C. parapsilosis 
(204) Amphotericin B 0.25–1.0 1.0 1.0 0 (0.00) 
 Fluconazole 0.125–64 0.5 4.0 11 (5.39) a 
 Voriconazole 0.03–2 0.03 0.125 3 (1.47) b 
 Caspofungin 0.125–64 1.0 2.0 12 (5.88) 
 Anidulafungin 0.03–64 1.0 2.0 7 (3.43) 
C. glabrata (134) Amphotericin B 0.25–1.0 0.5 1.0 0 (0.00) 
 Fluconazole 1.0–64 4.0 32 25 (18.67) 
 Voriconazole 0.03–4.0 0.125 0.5 3 (2.24) 
 Caspofungin 0.03–0.5 0.06 0.125 0 (0.00) 
 Anidulafungin 0.06–0.5 0.06 0.125 0 (0.00) 
C. tropicalis (106) Amphotericin B 
0.125–
1.0 0.5 1.0 0 (0.00) 
 Fluconazole 0.25– 
128 
1 2 2 (1.89) 
 Voriconazole 0.03–8 0.06 0.125 2 (1.89) 
 Caspofungin 0.03–0.5 0.06 0.125 0 (0.00) 
 Anidulafungin 0.03–0.5 0.03 0.125 0 (0.00) 
C. krusei (21) Amphotericin B 
0.125–
2.0 0.25 0.75 0 (0.00) 
 Fluconazole 16–128 4.0 8.0 21 (100.00) 
 Voriconazole 0.03–4.0 0.25 1.0 2 (9.52) 
 Caspofungin 0.125–8 0.125 1.0 1 (4.76) 
 Anidulafungin 0.03–8 0.06 0.25 1 (4.76) 
a All the isolates except one exhibit decreased susceptibility (SDD) to fluconazole. b All the isolates are 
SDD to voriconazole. 
Table 4. Antifungal susceptibility test results for selected species of Candida isolated during 
prospective, sentinel surveillance in Spain from June 2008 to June 2009 
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When  we considered the C. glabrata isolates obtained during the study only the 81.33% of 
them were were susceptible to fluconazole and 97.76% were susceptible to voriconazole, but 
on the contrary, 97.93% and 98.96% of the isolates of C. albicans were susceptible to 
fluconazole and voriconazole respectively. The proportion of isolates that was resistant to 
the studied azole drugs was comparable with that observed in the other recently published 
studies. (Messer et al., 2009, Pemán et al., 2011). 
The antifungal activities of voriconazole, fluconazole, amphotericin B, caspofungin and 
anidulafungin against the 984 Candida spp isolated during the study period are summarized 
in Table 4. Among the azole compounds, voriconazole was the most active drug overall 
with an MIC90 of 0.25 µg/ml. Against C. albicans, C. parapsilosis and C. tropicalis isolates, 
voriconazole (MIC90 range 0.03-0.25 µg/ml) was much more active than fluconazole 
(MIC90, 2-4). Although these differences in the drug activity, both azole compounds showed 
lower MICs for fluconazole and voriconazole for the species mentioned before when 
compared to C. glabrata and C. krusei isolates. Despite this good susceptibility profile, we 
found five Candida albicans isolates with a MIC greater than 4 µg/ml to voriconazole and 
two C. krusei isolates that had a voriconazole MIC of 2 ug/ ml. All these isolates were also 
resistant to fluconazole. 
We found that there was a statistically significant moderate linear correlation between 
fluconazole and voriconazole MICs (r = 0.574; P ≤ 0.01). having higher voriconazole MICs 
those isolates from patients who received fluconazole before the candidemia episode when 
compared to those without previous exposure to fluconazole (MIC90s of 0.25 µg/ml and 
0.06 µg/ml, respectively; P ≤ 0.05 
Table 5 summarize the risk factors we identified during the study with a candidemia 
episode due to an isolate with decreased susceptibility (SDD or resistant) to fluconazole 
using univariate statistical techniques.  
 
 No of isolates (%) 
susceptible to 
fluconazole 
No. of isolates (%) with decreased 
susceptibility or resistant to 
fluconazole 
P - value 
Neoplasia 27 (2.95) 6 (8.70) ≤ 0.01 
Neutropenia 37 (4.04) 11(15.94) ≤ 0.01 
Prior fluconazole use 27 (2.95) 10 (14.49) ≤ 0.01 
a Only statistically significant variables are summarized in the table 
Table 5. Summary of univariate statistical analysis between fluconazole susceptible isolates 
vs. resistant or SDD ones  
We found that this condition was associated with neoplasia (9% versus 3%; P ≤ 0.01), current 
neutropenia (16% versus 4%; P ≤ 0.01), and prior fluconazole use (14% versus 3%; P ≤ 0.001). 
These independent factors identified using the univariate statistical approach, were 
analyzed more deeply using a repeated measures logistic regression model. We obtained 
significant results for neoplasia (odds ratio, 2.9; 95% confidence interval, 1.4 to 5.9; P ≤ 0.05) 
and prior use of fluconazole (odds ratio, 3.8; 95% confidence interval, 1.7 to 8.2; P ≤ 0.01). 
(Table 6). 
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 Odds ratio 95 percent confidence Limits P - value 
Neoplasia 2.9 1.4 – 5.9 ≤ 0.05 
Prior fluconazole use 3.8 1.7 – 8.2 ≤ 0.01 
a Only statistically significant variables are summarized in the table. 
Table 6. Summary of multivariate statistical analysis of risk factors for candidemia caused 
by fluconazole susceptible isolates vs. resistant or SDD ones a 
Caspofungin and anidulafungin resistance was low (16 cases for caspofungin and 8 cases  
for anidulafungin) (Table 4). Despite this low rate of in vitro resistance to echinocandins  
of the isolates studied MICs from C. parapsilosis and C. guilliermondi were higher  
compared to the MIC obtained from other Candida spp. as it has been described in others 
studies. 
5. Antifungal treatment 
At the time of diagnosis and inclusion in this study, 122 case patients (12.3%) were receiving 
a systemic antifungal agent and were considered breakthrough infections (fluconazole, 78 
patients, amphotericin B, 31 patients, itraconazole and voriconazole, 3 patient each; and 
echinocandins, 5 patients). Although the reason for this high rate of breakthrough infections 
is not clear, it is possible that other factors besides the antifungal resistance have got a role in 
the explanation of this phenomenon. A deep analysis of these 122 cases showed that either 
the antifungal therapy duration or the election of the antifungal drug was inadequate. A 
total of 536 case patients (54.5%) received antifungal therapy, started at a median of 3 days 
from the Candida isolation or onset of candidemia. 
6. Mortality 
The crude mortality rate was 24.10%, but the mortality rate among children was 
significantly lower. (see Table 3) As it has been described in different studies published in 
the medical literature candidemia due to C. parapsilosis had a lower mortality rate than the 
rate due other Candida species (Morgan et al., 2005, Pappas et al., 2004, Pemán et al., 2002), 
but no statistically significant result when analyzing the death rate of patients infected by a 
susceptible isolate (54%) or a less-susceptible isolate (SDD or resistant) (64%) among 
patients who received fluconazole as treatment. (P ≤ 0.44). 
7. Discussion and remarks 
This prospective candidemia surveillance study represents one of the largest multicenter 
studies conducted in Spain and provide one of the most representative data on the 
epidemiology of candidemia to date. The first remarkable finding of our study was the 
higher incidence of candidemia than those reported from centers located in the Northern 
Hemisphere which ranged between 0.28 to 0.96 per 1,000 admissions (Banerjee et al., 1991, 
Doczi et al., 2002, Marchetti et al., 2002, Pfaller et al., 1998, Pfaller et al., 2004, Richet et al., 
2002, Sandven et al., 1998, Tortorano et al., 2002, Tortorano et al., 2004) and including those 
published before in Spain (0.76 to 0.81 per 1,000 admissions) (Almirante et al., 2005, Alonso-
Valle et al., 2003, Pemán et al., 2002, Pemán et al., 2011, San Miguel et al., 2005). Although 
the reasons for this high rate are not entirely clear, it is possible that this may be related to a 
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combination of multiple factors, including differences in medical care resources, 
transplantation programs, implementation of infection control measures in hospitals, 
empirical antifungal therapy and prophylaxis for high-risk patients. Another possibility is 
that our series may not reflect the current trends, but the data from a prospective study held in 
Spain and recently published by Peman et al. support our data (Pemán et al., 2011, Pfaller & 
Diekema, 2007) (see Table 7). 
 
Country and period 
Total 
number of 
isolates 
% of total by most representative species 
C. 
albicans 
C. 
parapsilosis 
C. 
tropicalis 
C. 
glabrata 
C. 
krusei 
USA 1992-1993 837 52 21 10 12 4 
USA 1993-1995 79 56 15 10 15 - 
USA 1995-1997 1593 46 14 12 20 2 
USA 1995-1998 934 53 10 12 20 3 
USA 1998-2000 935 45 13 12 24 2 
USA 2001-2004 2773 51 14 7 22 2 
USA 2008-2009 1354 48 17 10 18 2 
Canada 1992-94 415 69 10 7 8 1 
Latin America 1995-1996 145 37 25 24 4 1 
Latin America 2001-2004 1565 50 16 20 7 2 
Asia-Pacific 2001-2004 1344 56 16 14 10 2 
Taiwan 1994-2000 1095 50 14 21 12 <1 
Europe 1992-94 249 49 11 11 10 9 
Europe 1997-99 2089 56 13 7 14 2 
Europe 2001-2004 2515 60 12 9 10 5 
Norway 1991-2003 1415 70 6 7 13 2 
Denmark 2003-2004 307 63 4 4 20 3 
Spain 2002-2003 351 51 23 10 9 4 
Spain 2001-2006 1997 47 19 10 12 5 
Spain 2008-2009 984 49 21 13 11 2 
Spain 2009-2010 1377 45 29 12 8 2 
Table 7. Summary of geographical differences in species distribution in Candida BSI isolates. 
(Adapted and modified from Pemán et al., 2001 and Pfaller & Diekema, 2007). 
Despite this fact, it seems that probably a combination of factors may have affected the 
overall rates of fungemia cases in Spain. The differences appeared in the average age of our 
patients when compared to other surveillance series from the United States (Ostrosky-
Zeichner et al., 2003, Pappas et al., 2003), are probably due to the high proportion of children 
in our study, especially in the Spanish hospitals located in the Southern part of the country 
(32% of children in the Spanish hospitals from the Southern part of the country compared to 
9% described in the study from the United States) (data not shown). Therefore, this 
condition reflects that there are great differences among patients of different geographical 
locations as it was mentioned in the introduction and the demographical composition and 
lastly the risk factors, could be very different from one population to another. (Table 7). In 
fact, the number of cases of invasive candidemia was not homogeneous across the country., 
the distribution of the  clinical isolates obtained during the study period along four different 
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geographical areas in Spain,. (North, Center, East and South). C. albicans covers almost half 
(49.08%) of the global cases, remaining as the most frequently isolated specie, but the rates 
between the four different areas were not homogenous., for instance,  in the Southern part of 
the country the rate of isolates of C. albicans (39.2%) was similar to the one of C. parapsilosis 
(37.4%). 
Some studies have reported a shift in the etiology of candidemia reporting an increase of 
candidemia cases caused by non-albicans Candida species during the last decade (Colombo et 
al., 2006, Richet et al., 2002, Tortorano et al., 2004) (Table 7). Although C. albicans remain the 
most frequently isolated specie, reasons for the emergence of non-albicans species remain 
unclear, but some medical conditions may explain increasing incidence of candidemia due 
to non-albicans species. It has been noted in previous reports that infections due to C. 
tropicalis candidemia is associated with neoplasia and neutropenia (Komshian et al., 1989) 
and those attributable to C. parapsilosis are often associated with the presence of 
intravascular catheters and are not influenced by exposure to fluconazole or other 
antifungal agents (Clark et al., 2004, Girmenia et al., 1996, Levy et al., 1998, Sandven et al., 
1998).  The last situation, may us to consider C. parapsilosis as an exogenous pathogen and 
breaches of catheter care and of infection control practice should be investigated and revised 
within institutions where this species has become a common blood culture isolate. 
The increasing incidence some of non-albicans Candida species with reduced susceptibility to 
azoles, such as C. glabrata, creates new therapeutic challenges and leads to another 
important question such as the influence of previous antifungal therapy in the development 
of non-albicans species candidemia. Recent studies, such as those published by Marr et al. 
and Tortorano et al. had addressed this question and showed interesting results about the 
association with previous exposure to azoles and the risk of development of fungemias due 
to C. krusei and / or C. glabrata (Marr et al., 2000, Tortorano et al., 2004). In fact, the 
differences in antifungal susceptibilities among isolates between different regions in Spain 
was almost entirely attributable to high-level resistance to azoles observed among C. glabrata 
and C. krusei isolates (Table 4). 
We are not aware of these epidemiological changes mentioned in the paragraph above and 
our findings from our study are supportive of them. C. parapsilosis fungemia account for the 
large majority of non-albicans species (in the same manner that that been described for other 
European countries) and candidemia due to C. krusei is rare in Spain as it has been described 
in other series (Almirante et al., 2005, Alonso-Valle et al., 2003, Ostrosky-Zeichner et al., 
2003, Pemán et al., 2002, Pemán et al., 2011, Tortorano et al., 2004). The explanation for this 
species distribution in Spain which is more or less similar to other Latin American countries 
is not clear and perhaps many factors are involved. However, this species distribution has 
got a great importance in the developing of therapeutic schemes and in the prevention of 
antifungal resistance. 
While most non-albicans Candida species are associated with high fluconazole minimum 
inhibitory concentrations (MIC), C. parapsilosis is typically susceptible to most antifungals, 
although is associated with higher echinocandin MIC that vary between different agents. 
Moreover, the rate of persistently positive fungemia in patients treated with caspofungin 
was reported as almost double for C. parapsilosis versus other Candida species. Even more, if 
we consider clinical patients at risk of suffering a candidemia episode, such as 
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immunocompromised patients, where clinical responses are poorer the picture is not good. 
Summarizing, we are concerned about the use of echinocandins alone based on the 
identification of non-albicans Candida specie. Grouping these agents into one treatment 
scheme is difficult due to the variability not only in the susceptibility of the isolates, as well 
as the microbiological responses seen between different echinocandins.  
Regarding the susceptibility of the studied isolates, antifungal resistance was an infrequent 
finding in our study and was restricted to a few isolates, and none of them were resistant to 
amphotericin B. This condition is similar to the findings published in three recent studies 
(Almirante et al., 2005, Messer et al., 2009, Pemán et al., 2011). Our proportion of 
fluconazole-resistant isolates (6.32%) was low, similarly to the rate observed with Spanish 
(Almirante et al., 2005,  Pemán et al., 2011) European (5.2%) and North American isolates 
(6.6%) (Messer et al., 2009, Richardson & Lass-Flörl et al., 2008) (see Table 7). Mixing the 
ideas exposed above we can argue that the differences in the activity and susceptibility of 
the antifungal compounds studied suggest that azole drugs and echinocandins have got a 
complementary susceptibility profile. While azoles has got excellent in vitro activity to C. 
albicans, C. parapsilosis and C. tropicalis bloodstream isolates, echinocandins showed excellent 
activity against C. glabrata and C. krusei which are are associated with higher azole MICs. On 
the contrary, species with high MICs to echinocandins such as C. parapsilosis and C. 
guilliermondii showed excellent activity to azole agents. (Table 8).  
 
Specie of Candida 
Susceptibility to antifungal agent 
Amphotericin B Fluconazole Voriconazole Caspofungin Anidulafungin 
C. albicans S S S S S 
C. parapsilosis S S S S - I S – I 
C. glabrata S – NS S – SDD – R S – NS S S 
C. tropicalis S S S – NS S S 
C. krusei S R S S S 
a S, susceptible; NS, non-susceptible (intermediate for CLSI M27-A2 clinical breakpoints); SDD, sensitive 
dose-dependent; R, resistant. 
b The clinical breakpoints adopted in this table are those reflected in the CLSI M27-A2 methodology. No 
new clinical breakpoints or epidemiological cut-offs were used, in order to make the data comparable to 
the one reflected in our work. 
Table 8. Summary of commonly associated in-vitro susceptibility profiles for Candida spp. 
BSI isolates. (Adapted and modified from Richardson & Lass-Flörl, 2008) a, b 
These ideas are of great importance because previous exposure to fluconazole was a strong 
and independent factor associated with candidemia caused by fluconazole non-susceptible 
isolates as it had been reported previously by Marr et al. and Lin and colleagues and higher 
voriconazole MICs tended to be associated with prior exposure to fluconazole. Although 
these obtained results are statistically significant, they must be taken with some caution 
because the low resistant proportion of isolates in our study. However, they depict a 
situation of concern and illustrate the potential problem of cross-resistance between azoles 
with a direct impact in treatment failure and the outcome of the patient. Moreover, the 
potential for voriconazole resistant C. glabrata to emerge as a threat in people receiving 
voriconazole therapy and or prophylaxis has been raised in reports of breakthrough 
infections (Imhof et al., 2004, Pfaller et al., 2004). 
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Despite these concerning matters exposed above, voriconazole was the azole which 
exhibited the best in vitro antifungal activity in our study, and only one of six fluconazole-
resistant isolates was cross-resistant to voriconazole. The combination of a third generation 
azole such as voriconazole or posaconazole with an echinocandin could be of benefit for 
some patients, especially in those with persistent candidemia. 
The crude mortality rate observed in our study was similar to that reported in other series 
(Almirante et al., 2005, Colombo et al., 2006, Gudlaugsson et al., 2003, Pappas et al., 2003, 
Pfaller et al., 2004). Adults had higher mortality rates than pediatric patients (24.10% to 
16%). Similar to other reports, patients with C. parapsilosis candidemia had the lowest death 
rates (Nucci et al., 1998, Pappas et al., 2003).  
Summarizing, the epidemiological and susceptible data described along the text, document 
important differences and similarities in the epidemiology of candidemia in Spain compared 
to updated reports from other countries. This report shows that candidemia is a source of 
significant morbidity and mortality with high associated healthcare costs. Although our 
high rates of candidemia may be related to many factors, reasons for them are not clear and 
further study is necessary. Determining them may lead to identify potential measures that 
can help in disease prevention. In addition, our data support that fluconazole non-
susceptibility could be associated with prior fluconazole exposure and suggest that such 
exposure could lead to other new azoles cross-resistance and complicate the clinical 
outcome of some patients. 
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